ZymoGenetics (ZGEN) Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar
Tweet Send to a Friend
ZymoGenetics, Inc. (NASDAQ: ZGEN) announced positive final results from a Phase 2 clinical trial in patients receiving 2nd or 3rd ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
